NOVN.SW - Novartis AG
NEXT EARNINGS:
Apr 28, 2026
EPS Est: $2.12
|
Rev Est: $13.6B
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
Market Cap:
247.30B
Volume:
3,670,447
Avg Volume:
3,213,749
52 Week Range:
81.1-129.6
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.46
Last Dividend:
$3.70
Exchange:
SIX
Country:
CH
Employees:
75,883
IPO Date:
1995-08-03
EPS (TTM):
7.56
P/E Ratio:
18.30
Revenue (TTM):
57.13B
Total Assets:
115.49B
Total Debt:
37.01B
Cash & Equiv:
11.43B
Rev Growth (5Y):
2.7%
EPS Growth (5Y):
16.3%
FCF Growth (5Y):
10.7%
ROCE:
20.8%
Debt/Equity:
0.80
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $1.57 | $1.54 | +1.9% | $10.7B | $10.6B | +0.2% |
| 2025-10-27 | $1.81 | $1.83 | -1.1% | $11.4B | $11.2B | +2.3% |
| 2025-07-16 | $1.94 | $1.88 | +3.2% | $11.8B | $11.3B | +4.6% |
| 2025-04-29 | $1.88 | $1.74 | +8.0% | $12.0B | $10.8B | +11.4% |
| 2025-01-31 | $1.81 | $1.65 | +9.7% | $12.3B | $11.8B | +4.7% |
| 2024-10-29 | $2.06 | $1.95 | +5.6% | $11.3B | $11.1B | +1.8% |
| 2024-07-18 | $1.97 | $1.87 | +5.3% | $11.6B | $11.1B | +4.7% |
| 2024-04-23 | $1.80 | $1.67 | +7.8% | $11.0B | $10.4B | +5.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.13B | 51.72B | 46.66B | 43.46B | 43.97B | 49.90B | 48.68B | 46.10B | 43.40B | 49.44B | 50.39B | 53.63B |
| Net Income | 14.65B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.73B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B |
| EPS | 7.56 | 5.92 | 7.11 | 3.19 | 10.71 | 3.55 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 |
| Total Assets | 115.49B | 102.25B | 99.94B | 117.45B | 131.79B | 127.78B | 118.37B | 145.56B | 133.08B | 130.12B | 131.56B | 125.39B |
| Total Debt | 37.01B | 31.26B | 26.35B | 27.91B | 31.02B | 37.85B | 29.15B | 32.09B | 28.43B | 23.69B | 21.90B | 20.36B |
| Cash & Equivalents | 11.43B | 11.46B | 13.39B | 7.52B | 12.41B | 9.66B | 11.11B | 13.27B | 8.86B | 7.01B | 4.67B | 13.02B |
| Operating Cash Flow | 20.05B | 17.62B | 14.46B | 14.24B | 15.07B | 13.65B | 13.62B | 14.27B | 12.62B | 11.47B | 11.90B | 13.90B |
| Free Cash Flow | 18.43B | 13.80B | 11.71B | 11.56B | 12.10B | 11.06B | 11.37B | 10.92B | 9.88B | 8.60B | 8.05B | 10.19B |
| FCF per Share | 9.51 | 6.84 | 5.60 | 5.30 | 5.40 | 4.86 | 4.96 | 4.71 | 4.21 | 3.61 | 3.35 | 4.20 |
| Book Value | 46.10B | 44.05B | 46.67B | 59.34B | 67.66B | 56.60B | 55.47B | 78.61B | 74.17B | 74.83B | 77.05B | 70.77B |
| Cash & ST Investments | 11.58B | 13.35B | 13.96B | 18.61B | 28.11B | 11.29B | 11.23B | 15.96B | 9.48B | 7.78B | 5.45B | 13.86B |
| ROC Equity | 0.32 | 0.27 | 0.32 | 0.12 | 0.36 | 0.14 | 0.21 | 0.16 | 0.10 | 0.09 | 0.23 | 0.14 |